doc. MUDr. Ondřej Havránek, Ph.D.

doc. MUDr. Ondřej Havránek, Ph.D.

1st Faculty of Medicine of the Charles University
Head of Group Lymphoma Tumor Biology

After finishing my PhD in 2011, I worked more than six years full-time in B-cell lymphoma research at the Department of Lymphoma and Myeloma of the UT MD Anderson Cancer Center. Initially as a postdoctoral fellow and then as a research faculty (instructor). During those years, I learned many advanced and cutting-edge research methods (e.g. super resolution microscopy or genomics applications) and developed other techniques (applications of CRISPR/Cas9 for targeted genomic modifications or flow cytometry based FRET detection and calculation).

 It was a tremendous experience being involved in top lymphoma research that allowed me to grow in all aspects necessary for research, both professionally and personally, and my research on B-cell receptor signaling in lymphoma was recognized by selection for multiple oral presentations (e.g. American Society of Hematology Annual Meeting 2014, 2015, and 2016) and awards and recently featured on the cover of Blood. During the last year, I decided that I would like to use my research abilities and knowledge of its clinical relevance to establish my own independent research group in lymphoma biology, and I am grateful that I got the opportunity to start my own research group at the BIOCEV institute in January 2018. I am looking forward to address unresolved issues in lymphoma specific B-cell receptor and AKT signaling and investigate other novel ideas. At the same time, I will continue several projects in close collaboration with my former supervisor and other faculty members at the MD Anderson Cancer Center.

More information about my lab - HERE

Recent publications


Jain N, Singh S, Laliotis G, Hart A, Muhowski E, Kupcova K, Chrbolkova T, Khashab T, Chowdhury SM, Sircar A, Shirazi F, Singh RK, Alinari L, Zhu J, Havranek O, Tsichlis P, Woyach J, Baiocchi R, Samaniego F, Sehgal L. Targeting phosphatidylinositol 3 kinase-β and -δ for Bruton tyrosine kinase resistance in diffuse large B-cell lymphoma. Blood Adv 2020 Sep 22;4(18):4382-4392. (2019 IF 4.6)


Kleiblova P, Stolarova L, Krizova K, Lhota F, Hojny J, Zemankova P, Havranek O, Vocka M, Cerna M, Lhotova K, Borecka M, Janatova M, Soukupova J, Stribrna J, Sevcik J, Zimovjanova M, Kotlas J, Panczak A, Vesela K, Zidovska J, Cervenkova J, Schneiderova M, Burocziova M, Burdova K, Stranecky V, Foretova L, Machackova E, Tavandzis S, Kmoch S, Macurek L, Kleibl Z. Identification of deleterious germline CHEK2 mutations and their association with breast and ovarian cancer. Int J Cancer. 2019 Oct 1;145(7):1782-1797 (2019 IF=5.1)

Jain N, Harter K, Tadros S, Fiskus W, Havranek O, Ma MCJ, Bouska A, Heavican T, Kumar D, Deng Q, Moore D, Pak C, Liu CL, Gentles AJ, Hartmann E, Kridel R, Smedby E, Juliusson G, Rosenquist R, Gascoyne RD, Rosenwald A, Giancotti F, Neelapu SS, Westin J, Vose JM, Lunning MA, Greiner T, Rodig S, Iqbal J, Alizadeh AA, Davis RE, Bhalla K, Green MR. Targetable genetic alterations of TCF4 (E2-2) drive immunoglobulin expression in diffuse large B-cell lymphoma. Science Translational Medicine 2019 Jun 19;11(497) (2019 IF 16.3)

Prukova D, Andera L, Nahacka Z, Karolova J, Svaton M, Klanova M, Havranek O, Soukup J, Svobodova K, Zemanova Z, Tuskova D, Pokorna E, Helman K, Forsterova K, Pacheco-Blanco M, Vockova P, Berkova A, Fronkova E, Trneny M, Klener P. Co-targeting of BCL2 with venetoclax and MCL1 with S63845 is synthetically lethal in vivo in relapsed mantle cell lymphoma. Clin Cancer Res. 2019 Jul 15;25(14):4455-4465. (2019 IF 10.1)


Vangapandu HV, Havranek O, Ayres M, Wierda WG, Keating MJ, Davis RE, Stellrecht CM, Gandhi V. B-cell Receptor Signaling Regulates Metabolism in Chronic Lymphocytic Leukemia. Mol Cancer Res. 2017 Dec;15(12):1692-1703 (2016 IF 5.0)

Mathur R, Sehgal L, Havranek O, Kohrer S, Khashab T, Jain N, Burger JA, Neelapu SS, Davis RE, Samaniego F. Inhibition of demethylase KDM6B sensitizes diffuse large B-cell lymphoma to chemotherapeutic drugs. Haematologica. 2017 Feb;102(2):373-380 (2016 IF 7.7)


Havranek O, Xu J, Köhrer S, Wang Z, Becker L, Comer JM, Ma W, Westin JR, Ghosh D, Shinners N, Sun L, Karri AR, Burger JA, Zal T, Davis RE. Tonic B-Cell-Receptor Signaling in Diffuse Large B-Cell Lymphoma. Blood. 2017 Aug 24;130(8):995-1006 (Featured on the Cover, 2016 IF 13.2)

Koehrer S, Havranek O, Seyfried F, Hurtz C, Coffey GP, Kim E, Hacken E, Jäger U, Vanura K, O’Brien S, Thomas DA, Kantarjian H, Ghosh D, Wang Z, Zhang M, Ma W, Jumaa H, Debatin K, Müschen M, Meyer LH, Davis RE, Burger JA. Pre-BCR Signaling in Precursor B Cell Acute Lymphoblastic Leukemia regulates PI3K/AKT, FOXO1, and MYC, and can be targeted by SYK inhibition. Leukemia. 2016 Jun;30(6):1246-54 (2016 IF 11.7)


Havranek O, Kleiblova P, Hojny J, Lhota F, Soucek P, Trneny M and Kleibl Z. Association of germline CHEK2 gene variants with risk and prognosis of non-Hodgkin’s lymphoma. PLoS One. 2015 Oct 27;10(10) (2015 IF 3.1)